We serve Chemical Name:Potassium selenocyanate CAS:3425-46-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Potassium selenocyanate
CAS.NO:3425-46-5
Synonyms:Potassium selenocyanate;Potassium selenoisocyanate;K(selenocyanate);Selenocyanic acid, potassium salt (1:1);Selenocyanic acid potassium;Selenocyanic acid,potassium salt;EINECS 222-320-1;potassium selenocyanide;potassium ion selenocyanate;MFCD00011366;potassium(II) selenocyanate
Molecular Formula:CKNSe
Molecular Weight:144.076
HS Code:2929909090
Physical and Chemical Properties:
Melting point:147 °C
Boiling point:134.2ºC at 760 mmHg
Density:2.347
Index of Refraction:
PSA:23.79000
Exact Mass:144.883301
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3283 6.1/PG 2
Packing Group:II
Contact us for information like Potassium selenocyanate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,potassium(II) selenocyanate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Potassium selenocyanate Use and application,Selenocyanic acid, potassium salt (1:1) technical grade,usp/ep/jp grade.
Related News: With the closing of AstraZeneca’s mega $39 billion buyout of Alexion Pharmaceuticals this week, the U.K. pharma has officially picked up Soliris and its successor, Ultomiris. 3-phenylisothiazole-4-carbonitrile manufacturers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. methanesulfonohydrazide suppliers RELATED: With Takhzyro durability data, Takeda tries to fend off BioCryst’s hereditary angioedema challenger Orladeyo tungsten sulfide vendor & factory It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. ,Biogen’s Alzheimer’s drug, Aduhelm, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.
